Condition
Advanced Melanoma and Normal or Impaired
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Recruiting1
Terminated1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07027488Phase 1RecruitingPrimary
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT00543205Phase 2TerminatedPrimary
Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment
Showing all 2 trials